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Gynecological and obstetrical infectious diseases are an important 
component of women’s health. A system approach to gynecological and obstetrical 
infection helps unify and classify microbial etiology and pathogenesis within a 
clinical anatomical framework of lower and upper genital tract syndromes. The 
reproductive system of women includes the vulva, vagina, cervix, uterus, fallopian 
tubes and ovaries. During pregnancy additional tissues include the chorioamnion 
and placenta together with the fetus and amniotic fluid. We review in two parts 
reproductive system infection syndromes in women using selected research results 
to illustrate the clinical utility of the system approach in terms of diagnosis, 
treatment and prevention. We conclude that a reproductive system perspective will 
lead to improvements in understanding, management and prevention of these 
diseases. 
 
 Importance of Reproductive System Infections 
  
Women’s reproductive health is at the core of medicine and public health. 
The health of populations is a direct correlate of infant survival and women’s health 
is the major determinant of infant health1. Differences in disease risk between men 
and women and among women are determined by biologic differences such as in sex 
steroid hormones, anatomy, host defenses, genetic variation and the effects of 
reproduction. These differences interact with external influences on psychological 
development, sociocultural environment and economic status to generate 
differences in disease risk among men and women2. 
Reproduction determines the evolution of Homo sapiens with most of the 
burden of reproduction carried by women3. Infections of the reproductive system 
profoundly impact the demographic properties of populations by differential 
impacts on fertility and infant survival4. For instance both epidemiologic studies and 
mathematical modeling demonstrate that reproductive system infection due to 









ulib user on 08 June 2020
 
 
areas where these infections are common and untreated5, 6. Such demographic 
influences impact human evolution and shape host defences. As examples sexually 
transmitted diseases may have fostered monogamy in human communities and 
menstruation may have evolved as a defence against pathogens that breach the 
cervical barrier to enter the endometrial cavity4, 7. Furthermore adaptive and innate 
immunity may have been shaped by natural selection to reduce inflammatory 
damage to key structures such as the fallopian tubes. Many epidemiologic studies 
have reported both HLA and Toll-like receptor allelic variants that correlate with 
risk of pelvic inflammatory disease and its sequelae8-12.  Specifically polymorphisms 
in the genes encoding IL-12 , IL-10 and TNF  are linked with tubal infertility due 
to Chlamydia trachomatis13, 14. Although women with strong immune responses may 
be more likely to survive infection their reproductive effectiveness may be less 
successful than women who are not as responsive. Thus the range of immune 
variability seen in populations may be in part due to the effects of alternative 
phenotypes on inflammatory responses to reproductive system infections in 
women15. 
 To understand the clinical syndromes produced by infections of the 
reproductive system it is helpful to have an understanding of the immunology of the 





Infection can spread along the epithelial surfaces from the lower genital tract 
through the cervix to the upper genital tract or through the blood system to involve 
the entire reproductive system and fetus. Topologically the reproductive system of 
women is open to the external environment and numerous host defence 
mechanisms are in place to prevent acquisition and canalicular spread of infection. 
Such host defence mechanisms include low pH in the vagina due to a healthy 
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microbial transit except at mid cycle, during menstruation or post birth. Throughout 
the reproductive system the molecular components of the Toll-like receptor innate 
defence system are expressed on epithelial cells which when stimulated secrete pro-
inflammatory cytokines. As an example infection of epithelial cells by pathogens 
such as Chlamydia trachomatis result in the secretion of pro-inflammatory 
cytokines16. 
The adaptive immune system of the female reproductive system is linked to 
the systemic immune system at the induction phase of an immune response and to 
the common mucosal immune system at the effector phase. Anatomically the female 
reproductive system lacks organized lymphoid tissue as found in the 
gastrointestinal tract and antigen encounter between antigen presenting cells and 
naïve lymphocytes occur in regional lymph nodes such as the iliac and inguinal 
lymph nodes. However, antigen primed lymphocytes home back to mucosal surfaces 
providing long-term protection or contributing to immunopathology as sub-mucosal 
tissue resident T and B cells17.   As an example sub-mucosal tissue resident T cells 
can be readily isolated from the fallopian tubes of women with tubal infertility due 
to Chlamydia trachomatis infection and such T cells commonly secrete IL-10 when 
stimulated with Chlamydia trachomatis heat shock protein 6018, 19. Immune 
responses generated in response to reproductive system infection can also be 
detected in peripheral blood and are also correlated with immune phenotypes such 
as resistance to Chlamydia trachomatis reinfection20, 21 or to fallopian tube damage 
post Chlamydia trachomatis infection22, 23. Immune responses generated at other 
mucosal surfaces such as the oropharynx may also correlate with resistance to 
infection in the upper reproductive system mucosal sites in women24.  During 
pregnancy systemic cellular immune responses to microbial antigens are depressed 
putting pregnant women at heightened risk for reproductive system infection such 
as with Candida albicans25. Pregnancy also greatly alters the phenotype of upper 
genital tract infection. Pelvic inflammatory disease is rare in pregnant women 
because the choriamnion overlays the cervical mucous plug. Rather ascending 














Sexually Transmitted Disease Epidemiology 
 
In general reproductive system infection infections are either due to an 
intrinsic dysbiotic microbiome or to external pathogens most of which are sexually 
transmitted. A general model of sexually transmitted disease (STD) epidemiology is 
used to define control strategies27. STD epidemiology is determined by pathogen 
transmission as described by its reproductive number R0. For a sexually transmitted 
infection to spread in a population its reproduction number needs to exceed one. In 
a fully susceptible population R0 is determined by three parameters, each of which is 
the focus for pathogen specific control programs. 
R0 = cD 
 
is the transmission probability given contact between a susceptible and infected 
person, D is the average duration of infection and c is the average contact rate 
between an infected and susceptible person. Condom promotion and vaccines target 
reducing ; case finding and antimicrobial treatment target reducing D; and 
behavioural messages target changing c. In the absence of an effective STD control 
program and D are relatively stable characteristic for each pathogen; therefore the 
critical determinant of the reproductive number of an STD in a population is the 
frequency and pattern of sexual interaction between transmitter and new 
susceptible. Within a given population, the subset characterized by high rates of sex 
partner change is central to maintaining STDs within a population. This subset is 
found within an exceedingly small core of the population. Because STDs concentrate 
among individuals in the core, immune responses also concentrate in such 
individuals likely shaping the virulence and antigenic structure of STD pathogens28. 
Study of the antigen structure of STD pathogens has uncovered many of those 
molecules relevant to immunity and immunopathogenesis. In the case of Chlamydia 
trachomatis such studies have also uncovered molecules suitable for the 













Vaccines will be essential to STD control because of the extended duration of 
infection required to generate immune responses that clear infection and protect 
against reinfection30. The time to development of protective immunity after 
infection takes several months depending on the pathogen31. This phenomenon is 
particularly important for the bacterial sexually transmitted infections (Treponema 
pallidum, Neisseria gonorrhoeae, and Chlamydia trachomatis) because control 
programs based on detection and antimicrobial treatment reduce the average 
duration of infection and thereby reduce the probability of acquired immunity. This 
phenomenon which is clearly seen with Chlamydia trachomatis has been termed 
arrested immunity and contributes to the risk of reinfection32. Thus vaccines for the 
three major bacterial sexually transmitted infections will be essential to future 




Women’s reproductive system infections can be classified anatomically and 
involve the vulva, vagina, cervix, endometrium, fallopian tube, ovaries, 
chorioamnion, fetus, neonate and infant (Table 1). Reproductive system infections 
may be due to microbes due to microbes that arise from a dysbiotic vaginal 
microbiome or from exogenous pathogens that are sexually transmitted or via 
instrumentation of the reproductive system. The major microbial agents involved in 
reproductive system infections are shown in table 2.  
 A system perspective is a clinically useful approach to conceptualize 
gynecological and obstetrical infectious disease. While similar pathogens are 
involved in both gynecological and obstetrical infectious diseases the clinical 
syndromes differ between non-pregnant and pregnant women. This is most 
apparent in the upper genital tract syndromes. We summarize selected research in 
order to demonstrate the validity of the reproductive system approach and to 
highlight advancements in understanding reproductive system infectious diseases 
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clinical syndromes that define microbial diseases of the vulva, vagina and cervix. 
The second part focuses on clinical syndromes that define microbial diseases of the 






 Three different microbial syndromes are major causes of vulvar disease. 
These syndromes are genital ulcer disease, genital warts and vulvar vestibulitis.  We 
discuss genital ulcer disease and vulvar vestibulitis in this section and defer genital 
warts to discussion of cervical neoplasia since genital warts and cervical cancer are 
both caused by human papilloma virus. 
 
Genital Ulcer Disease 
 
 Treponema pallidum and herpes simplex virus are the major causes of genital 
ulcer disease worldwide. Haemophilus ducreyi, lymphogranuloma venereum and 
donovanosis are minor causes except in specific geographic areas. A substantial 
fraction of genital ulcer disease remains etiologically undefined. At a global level 
genital ulcer disease is the major co-factor facilitating the heterosexual transmission 
of human immunodeficiency virus (HIV) infection and control of Haemophilus 
ducreyi infection has been correlated with reduction in HIV transmission in Africa33. 
During pregnancy Treponema pallidum bacteremia (and HIV viremia) are the most 
important causes of fetal infection resulting in intra-uterine fetal death and 
stillbirth34. In the developed world heterosexual syphilis outbreaks in urban areas 
are extremely geographically clustered, linked to commercial sex work and to rising 
case rates of congenital syphilis35, 36. When control has been attempted with 
targeted mass treatment with oral azithromycin incomplete control followed by a 
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immunity to syphilis37. Such findings reinforce the conclusion that a vaccine will be 




 Vulvar vestibulitis is a chronic relapsing vulvar pain syndrome (vulvodynia). 
Affecting 10-15% of reproductive age women, it is the most common cause of 
dyspareunia. Vulvar vestibulitis or localized provoked vulvodynia is the major cause 
of vulvodynia where the inflammatory pathology is localized to the vulvar vestibule. 
The vulvar vestibule is composed of non-keratinized stratified squamous epithelium 
embryologically derived from the endoderm and is contiguous with urethral and 
bladder epithelium. The histopathology of vulvar vestibulitis includes lymphocytic 
and plasma cell infiltration together with hyperplasia of pain sensory nerve fibres38. 
Epidemiologically vulvar vestibulitis is strongly associated with a history of 
recurrent vulvovaginal candidiasis and other causes of vaginal discharge. Clinically 
vulvar vestibulitis is associated with signs of mild vestibular inflammation in 
association with marked pain hypersensitivity to light touch of the vestibule with a 
cotton tipped swab. Most women with the syndrome have Lactobacilli dominant 
vaginal microbiome without findings of vulvovaginal candidiasis or other causes of 
vaginal discharge. However 30 to 40% of women with vulvar vestibulitis have 
cutaneous hypersensitivity on skin testing with Candida albicans39. This is rarely 
found among women without this syndrome. It is likely that microbial antigens from 
pathogens such as Candida albicans produce a long lasting contact hypersensitivity 
immune reaction that underlies disease pathogenesis. While treatment with topical 
glucocorticosteroids, cromolyn, lidocaine or longterm oral flucanozole are 
ineffective, most severe cases respond to surgical resection of the vestibular 
epithelium40, 41. Improved treatment and prevention of vaginal infections with 
pathogens such Candida albicans among other microbes in addition to reducing 
















 Among reproductive age women a healthy vaginal microbiome composed of 
predominantly Lactobacilli and little or no obligate or facultative anaerobes 
provides defence against exogenous pathogens and promotes healthy pregnancy 42. 
A Lactobacilli vaginal microbiome is promoted by estrogen maturation of glycogen 
containing squamous epithelial cells. A Lactobacilli microbiome lowers vaginal pH 
and together with other innate host defenses prevents entrance of potentially 
pathogenic microorganisms into the lower genital tract.  
 Disturbance in the healthy vaginal microbiome underpins vaginal dysbiosis 
or vaginal infection. The four major syndromic causes of vaginal dysbiosis or 
infection are bacterial vaginosis, desquamative inflammatory vaginitis, 
trichomoniasis and vulvovaginal candidiasis. Of the four microbial syndromes only 
trichomoniasis is unequivocally sexually transmitted although Gardnerella vaginalis 
may be transmitted sexually. All but vulvovaginal candidiasis is characterized by 
loss of vaginal Lactobacilli42, 43.  
 
Bacterial Vaginosis and Desquamative Inflammatory Vaginitis 
 
 Bacterial vaginosis and desquamative inflammatory vaginitis are two 
common vaginal discharge clinical syndromes (Figure 1)42. While clinically 
distinctive they share several common features. They are both a dysbiosis of the 
vaginal microbiome with loss of vaginal Lactobacilli. Whether a woman is colonized 
with Gardnerella vaginalis or not likely determines whether bacterial vaginosis or 
desquamative inflammatory vaginitis develops following loss of Lactobacilli. They 
are both associated with chorioamnionitis, preterm birth and pelvic inflammatory 
disease. They are both diagnosed with wet mount microscopy of vaginal fluid. They 
both respond to treatment with topical clindamycin but remain subject to frequent 
















 Two major clinical syndromes characterize microbial diseases of the cervix. 





Mucopurulent cervicitis is clinically diagnosed at the bedside as mucopus in 
the cervical os or ex vivo on white tipped cotton swab with or without edema, 
erythema and friability in the contiguous area of endocervical columnar epithelium 
called ectopy (Figure 2). A junction zone between the stratified squamous 
epithelium of the vagina and the single cell columnar epithelial surface of the 
endocervix is established in fetal life and in the majority of young women is visible 
on the face of the ectocervix. During the early years following the onset of sexual 
activity and pregnancy this epithelial junction zone undergoes metaplasia and is 
ultimately replaced by stratified squamous epithelium over the entire face of the 
ectocervix. The major microbial causes of mucopurulent cervicitis are Chlamydia 
trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium44-46. Chlamydia 
trachomatis mucopurulent cervicitis often has endocervical mucopus together with 
tissue changes resulting in edematous, erythematous and friable ectopy. Neiserria  
gonorrhoeae mucopurulent cervicitis is more often associated with mucopus alone. 
HSV-2 can cause ulcerative cervicitis especially during primary infection when both 
ulcers and vesicles appear on the ectocervical face.  
 Before the introduction of Chlamydia trachomatis control programs most 
women with cervical Chlamydia trachomatis infection had clinically evident 
mucoprulent cervicitis44. After the establishment of control  programs the 
prevalence of mucopurulent cervicitis among women with cervical Chlamydia 
trachomatis infection dramatically declined suggesting that the clinical 









ulib user on 08 June 2020
 
 
the acquired immune response. As more Chlamydia trachomatis and Neisseria 
gonorrhoeae infections are detected and treated the prevalence of subclinical 
infection rise. In the case of Neiserria gonorrhoeae the rise of subclinical infection 
has been correlated with the rise in gonococcal strains that exhibit severe 
nutritional deficiencies that produce non-inflammatory infection47. Phenotypic 
changes in Chlamydia trachomatis have not been detected among strains causing 
asymptomatic infection versus those causing symptomatic syndromes such as 
mucopurulent cervicitis suggesting that the disease manifestations among 
Chlamydia trachomatis infected women are determined primarily by the host rather 
than the organism.  
 The cytologic and histologic features of mucopurulent cervicitis and cervical 
infection with Chlamydia trachomatis and Neiserria gonorrhoeae are well 
characterized. On Papanicolaou stain Chlamydia trachomatis cervical infection 
correlates with the presence of activated lymphocytes, histiocytes (antigen 
presenting macrophages and dendritic cells) and atypical metaplasia of endocervical 
cells48. On biopsy of the cervix Chlamydia trachomatis is associated with secondary 
lymphoid aggregates and plasmacytic infiltration49. 
 As mentioned when treatment of Chlamydia trachomatis infection became 
more commonplace, the prevalence of mucopurulent cervicitis and its correlation 
with Chlamydia trachomatis and Neiserria gonorrhoeae infection declined and 
presently, most cervical Chlamydia trachomatis infections are subclinical. Because of 
this and because of major advances in Chlamydia trachomatis diagnostics based on 
nucleic acid amplification tests and single dose treatment with azithromycin, 
emphasis in Chlamydia trachomatis control moved from clinical recognition to 
screening and treatment.  Since randomized control trials demonstrated that 
screening and treatment of Chlamydia trachomatis infection in women reduced the 
risk of pelvic inflammatory disease, large-scale public health programs based on 
screening and treatment to prevent infertility were launched50. Evaluation of large-
scale Chlamydia trachomatis control programs in two Canadian provinces, Manitoba 
and British Columbia demonstrated that screening reduced pelvic inflammatory 
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the effect of infection on case rates and pelvic inflammatory disease rates was 
paradoxical. During the early years of the control program, Chlamydia trachomatis 
case rates fell but in later years, case rates dramatically rose while pelvic 
inflammatory disease continued to fall54. Figure 3 shows these divergent changes in 
British Columbia. Reinfection rates also increased because of concentration of 
infection into geographic core groups53.  
We interpreted these data to suggest that the result of the Chlamydia 
trachomatis control program has been to shorten the average duration of infection 
and interrupt the evolving immune responses. Arresting immunity reduces herd 
immunity, increases susceptibility to reinfection and causes annual case rates to 
rise. Reducing the average duration of infection reduces the probability of spread of 
infection to the endometrium and fallopian tubes, thereby reducing pelvic 
inflammatory disease rates. Support for these conjectures come form observations 
that women who spontaneously clear Chlamydia trachomatis cervical infection are 
more resistant to reinfection than women who remain infected and are treated55. 
Randomized control trials show that Chlamydia trachomatis screening and 
treatment does not reduce case rates56 and seroepidemiological studies show that 
Chlamydia trachomatis control programs result in reduced prevalence but increased 
incidence57, 58. Thus a vaccine will likely be essential to achieving Chlamydia 
trachomatis control. Outer membrane proteins such as the Chlamydia trachomatis 
major outer membrane protein and the polymorphic outer membrane proteins are 
major T and B cell antigens59. It seems probable that a successful Chlamydia 
trachomatis can be developed based on these proteins despite the fact that they 




 The identification of human papilloma virus as the etiological agent of 
cervical cancer is the single greatest advance in women’s health in the last decades 
of the twentieth century. The identification of the virus immediately led to the 









ulib user on 08 June 2020
 
 
cancer prevention. Distinct genotypes of human papilloma virus cause vulvar warts 
and cervical neoplasia. There are over 100 genotypes of genital human papilloma 
viruses of which 13 are high- risk genotypes capable of producing cancer. 
Commonly human papilloma virus types 6 and 11 cause genital warts and types 16 
and 18 are the major causes of cervical cancer. Cancer causing genotypes of human 
papilloma virus encode oncogenic E6 and E7 viral genes that inhibit host cell 
tumour suppressor proteins p53 and Rb. Most women with high-risk cancer causing 
human papilloma virus infection do not develop cancer due to the development of 
immunity or the absence of facilitating cofactors. Human papilloma virus like 
particles engender immunity when used as vaccine. There are currently three types 
of human papilloma virus vaccines containing two, four or nine viral genotypes 
produced by two manufacturers. The success of the human papilloma virus vaccine 
has been extraordinary and heralds the possibility that human papilloma virus 
caused cancers can be eradicated globally. 
 Cofactors are involved in human papilloma virus oncogenesis even when 
infection occurs with a high risk genotype. Eliminating cofactors may also assist in 
preventing cervical neoplasia. Chlamydia trachomatis is one established cofactor 
that may increase oncogenesis by facilitating human papilloma virus integration 
into the host genome since Chlamydia trachomatis produces double strand 
chromosomal DNA breaks during intracellular infection61, 62. Dysbiotic vaginal flora 
with a loss of vaginal Lactobacilli is another possible cofactor that may promote 
human papilloma virus oncogenesis through an altered vaginal metabolome that 
changes gene expression in cervical epithelial cells63, 64. Polyamines produced 
during bacterial vaginosis strongly bind to host cell histones and may alter gene 
expression in human papilloma virus infected cells. Control of facilitating cofactors 




 Lower genital tract infection syndromes are both common and similar in 
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may be at enhanced risk of infection because of depressed cellular immune 
responses. In the next part (part two) we discuss upper genital tract infection 
syndromes. This is where non-pregnant and pregnant women most differ in disease 
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Figure 1: Features of healthy vaginal flora, bacterial vaginosis and desquamative 
inflammatory vaginitis. (A). Normal healthy cervicovaginal mucosa and small amount of 
vaginal discharge consistent with lactobacilli dominating. Note physiological cervical ectopy 
and clear cervical mucus. (B). Normal vaginal wet mount (400x). Note rod-like bacteria 
consistent with lactobacilli and lack of leukocytes. (C). Bacterial vaginosis. Note heavy milk-
like homogenous vaginal discharge with bubbles, consistent with gaseous byproducts of 
anaerobic bacteria. (D). Wet mount findings of bacterial vaginosis. (400x) Note vaginal 
epithelial cells covered by coccobacilli consistent with clue cells. Note lack of leukocytes. 
(E). Desquamative inflammatory vaginitis. Note heavy yellowish vaginal discharge and 
inflamed cervicovaginal mucosa. (F). Wet mount findings of desquamative inflammatory 
vaginitis (400x). Note high number of leukocytes (mononuclear leukocytes dominate) and 
















Figure 2: Diagnosis of pelvic inflammatory disease. The clinical diagnosis of pelvic 
inflammatory disease is based on the findings of pelvic tenderness on bimanual vaginal 
examination and of lower genital tract inflammation on speculum examination. Panel A 
shows mucopurulent endocervical discharge as seen on speculum examination. An area of 
endocervical columnar epithelium (ectopy) is seen on the face of the cervix. The epithelium 
is edematous and erythematous and bleeds easily when touched (friability). Panel B shows 
mucopurulent endocervical discharge as a yellow–green exudate on the tip of a Dacron 
swab (a positive swab test). Panels C and D show high-power microscopic examination of 
vaginal fluid, with clue cells typical of bacterial vaginosis (Panel C) and increased numbers 



















Figure 3: Shown are case rates for C. trachomatis infection (blue) among women between 
the ages of 15 to 39 years and clinical PID (red) among women between the ages of 14 to 44 
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